Actively Recruiting
A Trial of Varenicline for E-cigarette Cessation
Led by Yale University · Updated on 2025-12-17
326
Participants Needed
2
Research Sites
263 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
CONDITIONS
Official Title
A Trial of Varenicline for E-cigarette Cessation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Report daily use of an e-cigarette containing nicotine
- Live in Connecticut or South Carolina
- Be 18 years of age or older
You will not qualify if you...
- Regular use of other tobacco products besides e-cigarettes
- Medical contraindications for varenicline use
- Current treatment for tobacco cessation
- Lack proficiency in English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut, United States, 06520
Actively Recruiting
2
Hollings Cancer Center at MUSC (HCC)
Charleston, South Carolina, United States, 29425
Actively Recruiting
Research Team
L
Lisa Fucito, PhD
CONTACT
M
Michael Fatigate, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here